Welcome to the UPF Digital Repository

Attenuation by baclofen of nicotine rewarding properties and nicotine withdrawal manifestations

Show simple item record

dc.contributor.author Varani, Andrés P.
dc.contributor.author Aso Pérez, Ester
dc.contributor.author Machado Moutinho, Lirane
dc.contributor.author Maldonado, Rafael, 1961-
dc.contributor.author Balerio, Graciela N.
dc.date.accessioned 2016-01-22T07:54:58Z
dc.date.available 2016-01-22T07:54:58Z
dc.date.issued 2014
dc.identifier.citation Varani AP, Aso E, Moutinho LM, Maldonado R, Balerio GN. Attenuation by baclofen of nicotine rewarding properties and nicotine withdrawal manifestations. Psychopharmacology (Berl). 2014 Aug;231(15): 3031-40. DOI: 10.1007/s00213-014-3469-6
dc.identifier.issn 0033-3158
dc.identifier.uri http://hdl.handle.net/10230/25635
dc.description.abstract RATIONALE: Nicotine is a major active ingredient in tobacco and plays a major role in tobacco addiction. In rodents, repeated nicotine administration produces behavioral responses related to its addictive properties, such as reinforcing effects and physical dependence. OBJECTIVES: The aim of the present study was to evaluate the possible role of GABAB receptor in responses induced by repeated nicotine administration in Swiss Webster mice. RESULTS: Nicotine hydrogen tartrate salt (0.5 mg/kg, s.c.) administration induced rewarding properties in the conditioning place preference test. The GABAB receptor agonist, baclofen (3 mg/kg, i.p.) abolished the rewarding properties induced by nicotine hydrogen tartrate salt (0.5 mg/kg, s.c.). In addition, naloxone-precipitated nicotine withdrawal induced somatic manifestations, anxiety-like effects in the elevated plus maze test and dysphoric manifestations in the conditioned place aversion paradigm. Baclofen (2 and 3 mg/kg, i.p.) prevented the somatic manifestations and the anxiety-like effects associated with naloxone-precipitated nicotine withdrawal but not the dysphoric manifestations. CONCLUSIONS: These results showed that nicotine rewarding properties and negative aspects of nicotine withdrawal, such as anxiety-like effects and somatic manifestations, can be modulated by the GABAB receptor activity. This study now reveals a novel possible application of baclofen to develop new therapeutic strategies to achieve smoking cessation.
dc.description.sponsorship This work has been supported by grants from University of Buenos Aires (UBACyT B016 and UBACyT 2013-2016 Nº 20020120100244), CONICET (PIP 11420090100303), Spanish “Ministerio de Ciencia e Innovación” (#SAF2011-29864), “Instituto de Salud Carlos III” (RETICS: #RD06/0001/0001, #RD06/0001/1004), Plan Nacional sobre Drogas (PNSD#2009/026), the CatalanGovernment/n(SGR2009-00131), and the ICREA Foundation (ICREA Academia-2008). Andrés P. Varani is a doctoral fellow of the University of Buenos Aires (677/10).
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher Springer
dc.relation.ispartof Psychopharmacology (Berl). 2014 Aug;231(15): 3031-40
dc.rights © Springer (The original publication is available at www.springerlink.com)
dc.subject.other Àcid aminobutíric -- Farmacologia
dc.subject.other Nicotina
dc.subject.other Abús de substàncies
dc.subject.other Aminoàcids
dc.title Attenuation by baclofen of nicotine rewarding properties and nicotine withdrawal manifestations
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.1007/s00213-014-3469-6
dc.relation.projectID info:eu-repo/grantAgreement/ES/3PN/SAF2011-29864
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/acceptedVersion

This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account


Compliant to Partaking